Molecular Formula | C28H29ClN4O3
|
Molar Mass | 505.01 |
Specific Rotation(α) | D25 -28.7° (c = 1.0 in ethanol) |
Solubility | DMSO: soluble10mg/mL, clear |
Appearance | powder |
Color | orange-red |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
In vitro study | LY333531 significantly reduced the chance of HUVEC cell survival, and the effect of LY333531 on apoptotic cell death of HUVEC was significantly increased compared to the AGEs Group. Inhibition of PKC-beta could increase the expression level of Bax and Bad protein, and decrease the expression level of Bcl-2 protein. In addition, LY333531 decreased the ratio of Bcl-2/Bax. It promotes AGEs-induced endothelial cell apoptosis. The upregulation of Bax, Bad expression and Bcl-2, and the decrease of Bcl2/Bax ratio were all related to the apoptotic process. |
In vivo study | In streptozotocin-induced diabetic rats, 4 weeks of LY333531 treatment prevented the overactivation of PKCb2 and alleviated diastolic dysfunction. LY333531 inhibited the decreased expression of NO, Cav-2, p-AKT, p-eNOS and decreased the increased expression of O2-, nitrotyrosine, Cav-1, iNOS in myocardium. |